Clinical trial
A Phase III, Randomized, Parallel, Double-blind, and Non-inferiority Clinical Trial to Compare Efficacy and Safety of CinnaGen-liraglutide to Innovator Liraglutide Product (Victoza®) in Patients With Type II Diabetes (T2D)
NCT03421119 is registered in ClinicalTrials.gov with Cinnagen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Randomized, Parallel, Double-blind, and Non-inferiority Clinical Trial to Compare Efficacy and Safety of CinnaGen-liraglutide to Innovator Liraglutide Product (Victoza®) in Patients With Type II Diabetes (T2D)
- Lead sponsor
- Cinnagen
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- June 20, 2019
- Completion date
- December 1, 2019
- Enrollment
- 300 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.